skip to Main Content

Clinical Trial Combining Immunotherapy and Chemotherapy

Newsfeed image, light gray text on dark gray background
The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) today announced the first patients have begun treatment in a new pancreatic cancer multi-center clinical trial. To combat the nation’s third deadliest cancer, the phase 1b/2 open-label study will explore the combination of standard chemotherapy and two immunotherapy agents: an anti-PD-1 checkpoint inhibitor and a novel antibody targeting CD40, a protein that when activated can drive the immune system to attack tumors.

To bring this project to life, the Parker Institute and Cancer Research Institute have joined forces to collaborate with industry partner Bristol-Myers Squibb Company (BMS) and biotech company Apexigen, Inc. Read More . . .



Back To Top